Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157772184> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3157772184 abstract "Abstract Introduction: Androgen deprivation therapy (ADT) decreases bone mineral density and increases osteoporotic fracture (OsteoFx) risk. Hypothesis: To assess OsteoFx incidence most predictive of future OsteoFx among men with prostate cancer on ADT. Methods: 4370 electronic medical records were reviewed of adult men with prostate cancer on cancer therapy +/- anti-osteoporotic therapy (Anti-OsteoRx) from 2011–2019. Cancer therapy included ADT (anti-androgens, GnRH agonists & antagonists, orchiectomy) and supplemental cancer therapy (SupplRx) (prostatectomy, brachytherapy, radiation, immunotherapy, and chemotherapy). Anti-OsteoRx included bisphosphonates, denosumab, and parathyroid hormone analogs. Patients with other cancers within 5 years of initial visit, metastasis or traumatic fractures were excluded. Retrospective analysis was done to determine baseline characteristics, type and duration of ADT, Anti-OsteoRx, SupplRx, and OsteoFx incidence. Results: Fracture rate subgroups: • ADT only - Anti-OsteoRx 37/ 374 fractured (9.89%) • ADT only + Anti-OsteoRx 10/52 fractured (19.23%) • ADT + SupplRx + Anti-OsteoRx 2/19 fractured (10.53%) • ADT + SupplRx + Anti-OsteoRx 13/170 fractured (7.65%) Comparing fracture rates between subgroups: • Comparing ADT only +/- Anti-OsteoRx, statistical significance was observed with higher fracture rate in patients taking Anti-OsteoRx (19.23% vs. 9.89%, p < 0.044) • Comparing ADT + SupplRx +/- Anti-OsteoRx, no significant difference in fracture rates due to small number of fractures Comparing combined subgroups: • ADT +/- SupplRx + Anti-OsteoRx 12/71 (16.9%) fractured • ADT +/- SupplRx - Anti-OsteoRx 50/544 (9.19%) fractured • Statistically significant between groups fracture rates was observed (p= 0.042) in patients treated with Anti-OsteoRX. Discussion: Patients receiving Anti-OsteoRx, regardless of their prostate cancer therapies, had higher rates of fractures (16.9 vs. 9.19%, p= 0.042) due to their being selected for therapy based on greater clinical risks. The Anti-OsteoRx group had a higher percentage of glucocorticoid listed as a historical medication (26.8 vs.15.3% vs, p= 0.023), glucocorticoids administered (50.7 vs. 30.3% p=0.001), and anticonvulsants and proton-pump inhibitor use (45.1 vs. 26.5%, p= 0.002). Conclusion: Higher fracture rates were observed in patients on Anti-OsteoRx that could be related to their being selected for treatment based on risk factors known to be associated with osteoporosis. Limited Anti-OsteoRx use in our study is possibly related to lack of standardized guidelines for prevention of osteoporotic fractures in prostate cancer patients. OsteoFx risk assessment utilizing CRF, DXA, and FRAX may prevent fractures in these high-risk patients. Further long-term prospective studies to address these unresolved queries are warranted." @default.
- W3157772184 created "2021-05-10" @default.
- W3157772184 creator A5014730347 @default.
- W3157772184 creator A5044829086 @default.
- W3157772184 creator A5050784244 @default.
- W3157772184 creator A5054949258 @default.
- W3157772184 creator A5063565461 @default.
- W3157772184 creator A5068923930 @default.
- W3157772184 date "2021-05-01" @default.
- W3157772184 modified "2023-10-16" @default.
- W3157772184 title "Fracture Rates in Men With Non-Metastatic Prostate Cancer on Androgen Deprivation Therapy With or Without Anti-Osteoporosis Treatment" @default.
- W3157772184 doi "https://doi.org/10.1210/jendso/bvab048.501" @default.
- W3157772184 hasPublicationYear "2021" @default.
- W3157772184 type Work @default.
- W3157772184 sameAs 3157772184 @default.
- W3157772184 citedByCount "0" @default.
- W3157772184 crossrefType "journal-article" @default.
- W3157772184 hasAuthorship W3157772184A5014730347 @default.
- W3157772184 hasAuthorship W3157772184A5044829086 @default.
- W3157772184 hasAuthorship W3157772184A5050784244 @default.
- W3157772184 hasAuthorship W3157772184A5054949258 @default.
- W3157772184 hasAuthorship W3157772184A5063565461 @default.
- W3157772184 hasAuthorship W3157772184A5068923930 @default.
- W3157772184 hasBestOaLocation W31577721841 @default.
- W3157772184 hasConcept C120665830 @default.
- W3157772184 hasConcept C121332964 @default.
- W3157772184 hasConcept C121608353 @default.
- W3157772184 hasConcept C126322002 @default.
- W3157772184 hasConcept C126894567 @default.
- W3157772184 hasConcept C141071460 @default.
- W3157772184 hasConcept C143998085 @default.
- W3157772184 hasConcept C2776286101 @default.
- W3157772184 hasConcept C2776541429 @default.
- W3157772184 hasConcept C2777783956 @default.
- W3157772184 hasConcept C2777899217 @default.
- W3157772184 hasConcept C2779466945 @default.
- W3157772184 hasConcept C2780192828 @default.
- W3157772184 hasConcept C61511704 @default.
- W3157772184 hasConcept C71924100 @default.
- W3157772184 hasConceptScore W3157772184C120665830 @default.
- W3157772184 hasConceptScore W3157772184C121332964 @default.
- W3157772184 hasConceptScore W3157772184C121608353 @default.
- W3157772184 hasConceptScore W3157772184C126322002 @default.
- W3157772184 hasConceptScore W3157772184C126894567 @default.
- W3157772184 hasConceptScore W3157772184C141071460 @default.
- W3157772184 hasConceptScore W3157772184C143998085 @default.
- W3157772184 hasConceptScore W3157772184C2776286101 @default.
- W3157772184 hasConceptScore W3157772184C2776541429 @default.
- W3157772184 hasConceptScore W3157772184C2777783956 @default.
- W3157772184 hasConceptScore W3157772184C2777899217 @default.
- W3157772184 hasConceptScore W3157772184C2779466945 @default.
- W3157772184 hasConceptScore W3157772184C2780192828 @default.
- W3157772184 hasConceptScore W3157772184C61511704 @default.
- W3157772184 hasConceptScore W3157772184C71924100 @default.
- W3157772184 hasLocation W31577721841 @default.
- W3157772184 hasOpenAccess W3157772184 @default.
- W3157772184 hasPrimaryLocation W31577721841 @default.
- W3157772184 hasRelatedWork W11104898 @default.
- W3157772184 hasRelatedWork W15276436 @default.
- W3157772184 hasRelatedWork W17055214 @default.
- W3157772184 hasRelatedWork W17671018 @default.
- W3157772184 hasRelatedWork W18396566 @default.
- W3157772184 hasRelatedWork W18970280 @default.
- W3157772184 hasRelatedWork W19733631 @default.
- W3157772184 hasRelatedWork W20046256 @default.
- W3157772184 hasRelatedWork W21117391 @default.
- W3157772184 hasRelatedWork W3942566 @default.
- W3157772184 isParatext "false" @default.
- W3157772184 isRetracted "false" @default.
- W3157772184 magId "3157772184" @default.
- W3157772184 workType "article" @default.